ID   EFE-184
AC   CVCL_1191
SY   EFE184
DR   CLO; CLO_0002887
DR   CLDB; cl1140
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03470928
DR   BioSample; SAMN10987812
DR   CCLE; EFE184_ENDOMETRIUM
DR   Cell_Model_Passport; SIDM01502
DR   ChEMBL-Cells; CHEMBL3308103
DR   ChEMBL-Targets; CHEMBL1075438
DR   Cosmic; 924109
DR   Cosmic; 1576452
DR   Cosmic; 2030462
DR   DepMap; ACH-000435
DR   DSMZ; ACC-230
DR   GDSC; 924109
DR   GEO; GSM374971
DR   GEO; GSM375430
DR   GEO; GSM886997
DR   GEO; GSM888066
DR   IARC_TP53; 27153
DR   LiGeA; CCLE_747
DR   LINCS_LDP; LCL-1494
DR   PharmacoDB; EFE184_320_2019
DR   Wikidata; Q54832048
RX   PubMed=20164919;
RX   PubMed=20944090;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 90 hours (PubMed=25984343); ~92 hours (DSMZ).
CC   Sequence variation: Has no PTEN mutation (PubMed=20944090).
CC   Sequence variation: TP53 p.Arg282Trp (c.844C>T) (CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.39%; Native American=0.31%; East Asian, North=1.81%; East Asian, South=0%; South Asian=0%; European, North=58.73%; European, South=38.76% (PubMed=30894373).
CC   Derived from metastatic site: Ascites.
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 12
ST   D18S51: 12,19
ST   D21S11: 30,33.2
ST   D3S1358: 14,17
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 11,13
ST   FGA: 21
ST   Penta D: 10,13
ST   Penta E: 16
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C7558; Endometrial carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 24
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75-53ra75(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//